Clinical Trials List
2021-03-15 - 2025-12-31
Phase III
Recruiting7
ICD-10C78.5
Secondary malignant neoplasm of large intestine and rectum
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9197.5
Secondary malignant neoplasm of large intestine and rectum
-
Trial Applicant
Pharmaceutical Research Associates Taiwan Inc.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 梁逸歆 Division of Hematology & Oncology
- 陳國興 Division of Hematology & Oncology
- Kun-Huei Yeh Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 蔡祥麟 Division of Colorectal Surgery
- 黃敬文 Division of Colorectal Surgery
- Wei-Chih Su Division of Colorectal Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Peng-Chan Lin Division of Hematology & Oncology
- 陳柏全 Division of Colorectal Surgery
- 黃盈慈 Division of Hematology & Oncology
- Po-Wen Lin Division of Colorectal Surgery
- Shang-Hung Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林建良 Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
- 曹朝榮 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 蕭聖諺 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Chi Chou Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Mengting Peng Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
28 participants
-
Global
480 participants
